MAP2K7 and cancer: The efficacy of the combination strategy with debrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) was strongly demonstrated in NCI-MATCH Trial Subprotocol H. Overall, in this study, which enrolled patients with different cancer types harboring BRAF exon 15 p.V600 mutations, an ORR of 38% was reached [156].